The partners will combine Chembio's DPP technology and biomarkers developed at Mass General for diagnostic tests for typhoid and febrile illness.
The device uses neutrophil movement and its correlation with infection to detect sepsis. A commercial version could be several years away, however.
The polygenic score snags a greater percentage of people at risk of early heart attack than current tests that rely on single-gene variants or blood chemistry.
One firm, Exosome Diagnostics, is working to streamline payor coverage for a commercial test, and researchers are simultaneously developing promising ways to isolate exosomes.
The funding will be used to support the the newly established ME/CFS Collaborative Research Center at Stanford University.
The initiative's four research projects will use use genetic and other technologies to detect and treat cancer at its earliest stages.
The assay employs nanoplasmonics and protein-signal multiplexing in taking aim at early clinical detection of pancreatic ductal adenocarcinoma.
They have also developed an exosome-based test for high volume laboratory applications that was recently licensed by Exosome Diagnostics.
A microfluidic phone attachment developed at Brigham and Women's and Mass General may be the precursor of a fertility assay that men can use in the home.